MaxCyte® Flow Electroporation Enables Immunocytokine Manufacturing

Downlaod Application Note:

MaxCyte® Flow Electroporation Enables Immunocytokine Manufacturing

MaxCyte® Flow Electroporation Enables Immunocytokine Manufacturing

Explore how MaxCyte® enabled rapid, high-yield protein expression to generate novel cancer therapeutics. In this innovative study, Flow Electroporation® was used to generate fusion proteins called immunocytokines. The proteins were fully bioactive and produced in sufficient amounts for pre-clinical studies. Discover how effective these recombinant proteins were at treating solid tumors in mice.